Prevents bronchospasm with reversible obstructive airway disease. ANDA 207085, held by Sandoz. Albuterol Sulfate.
As of Nov 18, 2026, ANDA 207085 (Albuterol Sulfate), held by Sandoz, was first approved by FDA on Jun 1, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol sulfate inhalation aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 1, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Albuterol SulfateEQ 0.09MG BASE/INH · aerosol, metered;inhalation | Albuterol Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters